Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters.

Authors:
Address: Parasitology Division, Central Drug Research Institute, CSIR, Lucknow, Uttar Pradesh, India.
Journal:


Publication:
Free Text: Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters.

abstract

Visceral Leishmaniasis (VL), caused by the intracellular parasite Leishmania donovani, L. chagasi and L. infantum is characterized by defective cell-mediated immunity (CMI) and is usually fatal if not treated properly. An estimated 350 million people worldwide are at risk of acquiring infection with Leishmania parasites with approximately 500,000 cases of VL being reported each year. In the absence of an efficient and cost-effective antileishmanial drug, development of an appropriate long-lasting vaccine against VL is the need of the day. In VL, the development of a CMI, capable of mounting Th1-type of immune responses, play an important role as it correlate with recovery from and resistance to disease. Resolution of infection results in lifelong immunity against the disease which indicates towards the feasibility of a vaccine against the disease. Most of the vaccination studies in Leishmaniasis have been focused on promastigote--an infective stage of parasite with less exploration of pathogenic amastigote form, due to the cumbersome process of its purified isolation. In the present study, we have isolated and purified splenic amastigotes of L. donovani, following the traditional protocol with slight modification. These were fractionated into five membranous and soluble subfractions each i.e MAF1-5 and SAF1-5 and were subjected for evaluation of their ability to induce cellular responses. Out of five sub-fractions from each of membrane and soluble, only four viz. MAF2, MAF3, SAF2 and SAF3 were observed to stimulate remarkable lymphoproliferative, IFN-γ, IL-12 responses and Nitric Oxide production, in Leishmania-infected cured/exposed patients and hamsters. Results suggest the presence of Th-1 type immunostimulatory molecules in these sub-fractions which may further be exploited for developing a successful subunit vaccine from the less explored pathogenic stage against VL.



Related Articles
Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.
Clin Exp Immunol. 2005
Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.
Garg R, Gupta SK, Tripathi P, Naik S, Sundar S, Dube A. Clin Exp Immunol. 2005 Apr; 140(1):149-56.
Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
Vaccine. 2006
Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
Garg R, Gupta SK, Tripathi P, Hajela K, Sundar S, Naik S, Dube A. Vaccine. 2006 Apr 5; 24(15):2900-9. Epub 2006 Jan 17.
Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.
Vaccine. 2008
Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.
Kumari S, Samant M, Khare P, Sundar S, Sinha S, Dube A. Vaccine. 2008 Sep 2; 26(37):4813-8. Epub 2008 Jul 24.
Review Serodiagnosis of leishmaniasis.
Crit Rev Microbiol. 1995
Review Serodiagnosis of leishmaniasis.
Kar K. Crit Rev Microbiol. 1995; 21(2):123-52.
Review Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
Curr Drug Targets. 2008
Review Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
Kumari S, Kumar A, Samant M, Singh N, Dube A. Curr Drug Targets. 2008 Nov; 9(11):938-47.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.